Verastem to Present at Keystone Symposia on PI3 Kinase
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., (NAS: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of data at the Keystone Symposia on "PI3-Kinase and Interplay with Other Signaling Pathways" being held February 24 - March 1, 2013, in Keystone, Colorado.
The details of the Verastem poster presentation are as follows:
Title: The dual PI3K/mTOR inhibitor VS-5584 displays potent anticancer activities with preferential targeting of cancer stem cells
Date: Wednesday, February 27, 2013, from 3:00-10:00pm MT
Session: Poster Session 3
Poster Number: 3042
Location: Quandary Peak
About Verastem, Inc.
Verastem, Inc. (NAS: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
KEYWORDS: United States North America Massachusetts
The article Verastem to Present at Keystone Symposia on PI3 Kinase originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.